multimmune GmbH

..........delivering innovative cancer theranostics

NEWS

June 2018

Graham Pockley to present at the European Oncology Convention (London, 6-7 June 2018) 

May 2018

Graham Pockley to present at the 3rd Annual Advances in Immuno-oncology Congress (London, 24-25 May 2018) 

February 2018

Graham Pockley to present at the 13th Annual Biomarkers Congress (Manchester, UK; 15-16 February 2018).

September 2017

Graham Pockley presents on the theranostic potential of multimmune's platform technologies at the 4th Global Precision Medicine & Biomarker Summit (Munich, 21-22 September 2017)

May 2017

Graham Pockley presents on the theranostic potential of multimmune's platform technologies at the 2nd Annual Advances in Immuno-oncology Congress - Scientific Advisory Panel (London, 15-16 May 2017). He was also a member of the Scientific Advisory Panel)

March 2017

Graham Pockley presents on the theranostic potential of multimmune's platform technologies at the' Next Gen Immuno-Oncology Congress in London (13-14 March 2017. He was also a member of the Scientific Advisory Board Member)

May 2016

Graham Pockley presents on the theranostic potential of multimmune's platform technologies at the 'Advances in Immuno-Oncology' Congress in London (May 12-13)

November 2015

Gabriele Multhoff publishes new data on the mi-lipHsp70dx diagnostic assay: Correlation of Hsp70 serum levels with gross tumor volume and composition of lymphocyte subpopulations in patients with squamous cell and adeno non-small cell lung cancer

October 2015

Professor A. Graham Pockley, PhD appointed as CEO of multimmune GmbH. More details on Graham Pockley can be found here

September 2015

CESAR Prize 2015 awarded to Prof. Dr Gabriele Multhoff at a ceremony in Innsbruck, Austria


August 2015

SMi Group release interview with Professor A. Graham Pockley

Recruiting into a Phase II clinical trial for the treatment of non small lung cell carcinoma in 7 centres across Germany